http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102558337-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57fa60a0cac09d94577be5413e9c1e30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-08 |
| filingDate | 2012-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c8d803efebcfed8f73e034df226da7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a55805bc5663e452dd7b21fb390eee00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28f76bbc531ba04e129df13f63b1e10e |
| publicationDate | 2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102558337-B |
| titleOfInvention | Interferon alpha mutant and polyethylene glycol derivative thereof |
| abstract | The invention belongs to the field of biomedicine and relates to an interferon alpha mutant, a polyethylene glycol derivative thereof, a preparation method and a medicinal composition of the polyethylene glycol derivative, and application of the interferon alpha mutant and the polyethylene glycol derivative to preparation of medicines for treating virus diseases. The composite interferon cysteine mutant is prepared by mutating amino acid from one of the 75th to the 77th position based on the N terminal from the composite interferon amino acid sequence into cysteine. The polyethylene glycol derivative of the composite interferon cysteine mutant is prepared by connecting the composite interferon cysteine mutant with a polyethylene glycol modifier, wherein the molecular weight of the polyethylene glycol modifier is between 5 KDa and 40 KDa. The composite interferon cysteine mutant and the polyethylene glycol derivative thereof have higher bioactivity, better pharmacological effects, higher stability and more reliable safety. |
| priorityDate | 2012-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.